Seeking Alpha

Ligand Pharmaceuticals (LGND +6.9%) gains today after reporting positive results from...

Ligand Pharmaceuticals (LGND +6.9%) gains today after reporting positive results from preclinical studies using its HepDirect liver-targeting technology platform for the treatment of hepatitis C. According to the data, LGND's HepDirect prodrug of 2'-C methylguanosine, LG-7501, may be effective in improving the effectiveness of hep C treatment while reducing systemic side effects.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector